Late onset Lysosomal Storage Disorders (LSDs) in the differential diagnosis of neurodegenerative diseases: development of new diagnostic procedures and focus on potential pharmacological chaperones (PCs)
LYSOLATE
Funded by: Regione Toscana
Calls: BANDO RICERCA SALUTE 2018
Start date: 2020-07-17 End date: 2025-01-16
Total Budget: EUR 720.000,00 INO share of the total budget: EUR 100.000,00
Scientific manager: Amelia Morrone and for INO is: Calamai Martino
Organization/Institution/Company main assignee: Azienda Ospedaliero Universitaria Meyer di Firenze
Calls: BANDO RICERCA SALUTE 2018
Start date: 2020-07-17 End date: 2025-01-16
Total Budget: EUR 720.000,00 INO share of the total budget: EUR 100.000,00
Scientific manager: Amelia Morrone and for INO is: Calamai Martino
Organization/Institution/Company main assignee: Azienda Ospedaliero Universitaria Meyer di Firenze
other Organization/Institution/Company involved:
AOU Careggi
USL Toscana Centro
Universitá di Firenze
other INO’s people involved: Capitini ClaudiaCicchi RiccardoCredi CaterinaDallari Caterina
Abstract: Lysosomal storage diseases (LSDs) are rare or ultra-rare monogenic disorders. Their incidence is probably underestimated and the diagnosis is often delayed or may be missed because many symptoms are of a general, non-specific. In adults, several common neurodegenerative disorders (Parkinson’s disease, Alzheimer’s disease) can present symptoms similar to LSDs.
The main goal of this project is to characterize the symptoms of neurodegenerative diseases which overlap with late- onset LSDs, so that available treatments can be introduced before neurological deterioration progresses.
The aim of the CNR unit is to develop new methods for the diagnosis of some LSDs. It has been demonstrated that a misregulation of GM1 content is directly involved in Hungtinton’s and Parkinson’s diseases. A diagnostic test to measure GM1 ganglioside levels in peripheral blood represents a potential diagnostic tool for a number of common neurodegenerative diseases. The reprogramming and differentiation of induced pluripotent stem cells in neurons obtained from fibroblasts of LSD patients will lead to the development of a tool for evaluating any therapy for neurodegenerative diseases.
The main goal of this project is to characterize the symptoms of neurodegenerative diseases which overlap with late- onset LSDs, so that available treatments can be introduced before neurological deterioration progresses.
The aim of the CNR unit is to develop new methods for the diagnosis of some LSDs. It has been demonstrated that a misregulation of GM1 content is directly involved in Hungtinton’s and Parkinson’s diseases. A diagnostic test to measure GM1 ganglioside levels in peripheral blood represents a potential diagnostic tool for a number of common neurodegenerative diseases. The reprogramming and differentiation of induced pluripotent stem cells in neurons obtained from fibroblasts of LSD patients will lead to the development of a tool for evaluating any therapy for neurodegenerative diseases.
The Scientific Results:
1) Fluorescent In Situ Staining and Flow Cytometric Procedures as New Pre-Diagnostic Tests for Sialidosis, GM1 Gangliosidosis and Niemann-Pick Type C
